• Disc Medicine flagged initial Phase 2 RESTORE-PV data for DISC-3405 in polycythemia vera for presentation at SOHO 2026.
• Results have not been presented yet; an oral update is scheduled for Sept. 10, 2026, with a poster on Sept. 9.
• Planned disclosure covers baseline and safety from 40 patients, with pharmacology and early efficacy readouts from the first 20.
• Company also plans to present initial Phase 2 RALLY-MF efficacy findings for DISC-0974 to treat anemia in myelofibrosis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disc Medicine Inc. i published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608311800PRIMZONEFULLFEED9818866) on August 31, 2026, and is solely responsible for the information contained therein.